Table 1.
Baseline characteristics by study population and racea
| Characteristic | ARIC
|
FHS | HAPI | |
|---|---|---|---|---|
| White | Black | |||
| Sample size (n) | 11,061b | 4014b | 2468b | 861b |
| Age (yr; mean [SD]) | 54.4 (5.7) | 53.5 (5.8) | 61.0 (9.6) | 43.7 (13.9) |
| Male (%) | 47.2 | 38.2 | 53.0 | 53.4 |
| Diabetes (%) | 9.1 | 19.5 | 11.7 | 0.58 |
| Fasting glucose (mg/dl; mean [SD]) | 104.8 (29.1) | 112.6 (45.4) | 104.4 (26.7) | 86.2 (9.4) |
| BMI (kg/m2; mean [SD]) | 27.0 (4.9) | 29.6 (6.1) | 28.2 (5.4) | 26.6 (4.5) |
| Waist circumference (cm; mean [SD]) | 96.2 (13.4) | 99.1 (15.2) | 99.8 (14.2) | 87.3 (10.9) |
| SBP (mmHg; mean [SD]) | 118.5 (17.0) | 128.6 (21.3) | 126.9 (18.7) | 121.0 (14.6) |
| Anithypertensive medication (%) | 19.9 | 40.5 | 33.6 | 0.23 |
| Serum creatinine (mg/dl; mean [SD]) | 0.85 (0.2) | 0.93 (0.75) | 0.88 (0.28) | 0.84 (0.15) |
| eGFR (ml/min per 1.73 m2 at baseline; mean [SD]) | 89.6 (17.9) | 102.6 (24.8) | 84.7 (19.1) | 96.0 (18.5) |
| eGFR <60 at baseline (n [%]) | 326 (3.0) | 109 (2.8) | 193 (8.1) | 13 (1.5) |
| eGFR (ml/min per 1.73 m2) at visit 4 (mean [SD]) | 80.6 (17.0) | 89.4 (22.0) | N/A | N/A |
| eGFR <60 at visit 4 (n [%]) | 754 (8.7) | 166 (6.9) | N/A | N/A |
| ACR (mg/g; median [25th, 75th percentiles])c | 3.9 (2.0, 7.7) | 2.7 (0.9, 8.8) | 6.4 (2.8, 14.9) | N/A |
| Serum cystatin C (mg/L; mean [SD]) | N/A | N/A | 0.97 (0.24) | N/A |
a
BMI, body mass index, SBP, systolic BP; ACR, urinary albumin-to-creatinine ratio.
b
Number of observations with missing characteristic (ARIC white/ARIC black/FHS/HAPI): Diabetes (18/83/46/0), fasting glucose (250/372/131/395), BMI (7/9/49/0), SBP (6/3/2/0), antihypertensive medication (4/4/2/0), eGFR and serum creatinine (4/85/92/0), ACR (2481/1580/486/N/A), and cystatin C (N/A/N/A/138/N/A). In FHS, 109 (100) participants were missing genotype data at rs12255372 (rs7903146).
c
ACR was measured at ARIC study visit 4 and FHS examination cycle 6.